Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367173838> ?p ?o ?g. }
- W4367173838 endingPage "293" @default.
- W4367173838 startingPage "276" @default.
- W4367173838 abstract "Abstract The safety and efficacy of combining the isocitrate dehydrogenase-1 (IDH1) inhibitor ivosidenib (IVO) with the BCL2 inhibitor venetoclax (VEN; IVO + VEN) ± azacitidine (AZA; IVO + VEN + AZA) were evaluated in four cohorts of patients with IDH1-mutated myeloid malignancies (n = 31). Most (91%) adverse events were grade 1 or 2. The maximal tolerated dose was not reached. Composite complete remission with IVO + VEN + AZA versus IVO + VEN was 90% versus 83%. Among measurable residual disease (MRD)–evaluable patients (N = 16), 63% attained MRD-negative remissions; IDH1 mutation clearance occurred in 64% of patients receiving ≥5 treatment cycles (N = 14). Median event-free survival and overall survival were 36 [94% CI, 23–not reached (NR)] and 42 (95% CI, 42-NR) months. Patients with signaling gene mutations appeared to particularly benefit from the triplet regimen. Longitudinal single-cell proteogenomic analyses linked cooccurring mutations, antiapoptotic protein expression, and cell maturation to therapeutic sensitivity of IDH1-mutated clones. No IDH isoform switching or second-site IDH1 mutations were observed, indicating combination therapy may overcome established resistance pathways to single-agent IVO. Significance: IVO + VEN + AZA is safe and active in patients with IDH1-mutated myeloid malignancies. Combination therapy appears to overcome resistance mechanisms observed with single-agent IDH-inhibitor use, with high MRD-negative remission rates. Single-cell DNA ± protein and time-of-flight mass-cytometry analysis revealed complex resistance mechanisms at relapse, highlighting key pathways for future therapeutic intervention. This article is highlighted in the In This Issue feature, p. 247" @default.
- W4367173838 created "2023-04-28" @default.
- W4367173838 creator A5000109406 @default.
- W4367173838 creator A5000750846 @default.
- W4367173838 creator A5001280828 @default.
- W4367173838 creator A5007503457 @default.
- W4367173838 creator A5013173470 @default.
- W4367173838 creator A5016368595 @default.
- W4367173838 creator A5020340537 @default.
- W4367173838 creator A5022003021 @default.
- W4367173838 creator A5022201389 @default.
- W4367173838 creator A5023296232 @default.
- W4367173838 creator A5026202651 @default.
- W4367173838 creator A5029257506 @default.
- W4367173838 creator A5035605515 @default.
- W4367173838 creator A5036637982 @default.
- W4367173838 creator A5042269275 @default.
- W4367173838 creator A5049385583 @default.
- W4367173838 creator A5051949215 @default.
- W4367173838 creator A5054408146 @default.
- W4367173838 creator A5055045706 @default.
- W4367173838 creator A5056317446 @default.
- W4367173838 creator A5061026876 @default.
- W4367173838 creator A5065770077 @default.
- W4367173838 creator A5069176297 @default.
- W4367173838 creator A5080350639 @default.
- W4367173838 creator A5088234044 @default.
- W4367173838 creator A5090435894 @default.
- W4367173838 creator A5091492845 @default.
- W4367173838 date "2023-04-26" @default.
- W4367173838 modified "2023-10-16" @default.
- W4367173838 title "A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies" @default.
- W4367173838 cites W1622378427 @default.
- W4367173838 cites W1847894796 @default.
- W4367173838 cites W1993835819 @default.
- W4367173838 cites W2023014046 @default.
- W4367173838 cites W2058585360 @default.
- W4367173838 cites W2066640259 @default.
- W4367173838 cites W2078972833 @default.
- W4367173838 cites W2152496375 @default.
- W4367173838 cites W2159507916 @default.
- W4367173838 cites W2419140434 @default.
- W4367173838 cites W2517675534 @default.
- W4367173838 cites W2519326001 @default.
- W4367173838 cites W2738831299 @default.
- W4367173838 cites W2760499085 @default.
- W4367173838 cites W2806682325 @default.
- W4367173838 cites W2884819478 @default.
- W4367173838 cites W2889098804 @default.
- W4367173838 cites W2902652978 @default.
- W4367173838 cites W2906939534 @default.
- W4367173838 cites W2956213465 @default.
- W4367173838 cites W2995123606 @default.
- W4367173838 cites W3000515035 @default.
- W4367173838 cites W3001120382 @default.
- W4367173838 cites W3021794778 @default.
- W4367173838 cites W3048827006 @default.
- W4367173838 cites W3093815480 @default.
- W4367173838 cites W3094802395 @default.
- W4367173838 cites W3131535883 @default.
- W4367173838 cites W3146541588 @default.
- W4367173838 cites W3162324164 @default.
- W4367173838 cites W3164043037 @default.
- W4367173838 cites W3169558357 @default.
- W4367173838 cites W3190904657 @default.
- W4367173838 cites W3194828795 @default.
- W4367173838 cites W3212777568 @default.
- W4367173838 cites W4200058484 @default.
- W4367173838 cites W4200103238 @default.
- W4367173838 cites W4206683160 @default.
- W4367173838 cites W4224290890 @default.
- W4367173838 cites W4281569605 @default.
- W4367173838 cites W4284884567 @default.
- W4367173838 cites W4285719527 @default.
- W4367173838 cites W4286512367 @default.
- W4367173838 cites W4376595466 @default.
- W4367173838 doi "https://doi.org/10.1158/2643-3230.bcd-22-0205" @default.
- W4367173838 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37102976" @default.
- W4367173838 hasPublicationYear "2023" @default.
- W4367173838 type Work @default.
- W4367173838 citedByCount "10" @default.
- W4367173838 countsByYear W43671738382022 @default.
- W4367173838 countsByYear W43671738382023 @default.
- W4367173838 crossrefType "journal-article" @default.
- W4367173838 hasAuthorship W4367173838A5000109406 @default.
- W4367173838 hasAuthorship W4367173838A5000750846 @default.
- W4367173838 hasAuthorship W4367173838A5001280828 @default.
- W4367173838 hasAuthorship W4367173838A5007503457 @default.
- W4367173838 hasAuthorship W4367173838A5013173470 @default.
- W4367173838 hasAuthorship W4367173838A5016368595 @default.
- W4367173838 hasAuthorship W4367173838A5020340537 @default.
- W4367173838 hasAuthorship W4367173838A5022003021 @default.
- W4367173838 hasAuthorship W4367173838A5022201389 @default.
- W4367173838 hasAuthorship W4367173838A5023296232 @default.
- W4367173838 hasAuthorship W4367173838A5026202651 @default.
- W4367173838 hasAuthorship W4367173838A5029257506 @default.
- W4367173838 hasAuthorship W4367173838A5035605515 @default.
- W4367173838 hasAuthorship W4367173838A5036637982 @default.